Diversion and Abuse of Buprenorphine

More documents

Recommendations

Info

Exhibit 36. DAWN Live! Emergency Department Reports of Buprenorphine Including Metro Areas that No Longer Report to DAWN: 2003-2005 Atl Balt Bos Buf Chi Cle DFW Den Det Hou Lax Mia Minn NO NY Phil Phx SanD Sfo SEA STL DCA 0 10 20 30 40 50 60 70 80 The unweighted data are from all U.S. EDs reporting to DAWN. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted, and, therefore, are subject to change. SOURCE: DAWN, OAS, SAMHSA, downloaded 2/12/2006. Buprenorphine Assessment: Final Report 56
3000 2500 2000 1500 1000 500 0 Exhibit 37. Items Analyzed by Forensic Laboratories and Reported through NFLIS: 2002 HYDROCODONE METHADONE OXYCODONE BUPRENORPHINE A A A A C C C D D F G H I I I I K K L M M M M M M M M N N N N N N O O O P P S S T T U V W W W W K L R Z A O T C E L A I A D L N S Y A A D E I N O S T C E J M V Y H K R A R C D N X T A A I V Y Source: U.S. Drug Enforcement Administration, National Forensic Laboratory Information System Buprenorphine Assessment: Final Report 57
Page 1:
Diversion and Abuse of Buprenorphin
Page 5 and 6:
Diversion and Abuse of Buprenorphin
Page 7 and 8:
The actual review of the literature
Page 9 and 10: Risk Factors: The use of buprenorph
Page 11 and 12: prescribed dose to other persons wh
Page 13 and 14: In a separate report of data gather
Page 15 and 16: leading to heavy reliance on office
Page 17 and 18: 1. While adverse drug events associ
Page 19 and 20: At Columbia University, Herbert Kle
Page 21 and 22: Bridge TP, Fudala PJ, Herbert S et
Page 23 and 24: Gaul & Flaherty (2003b). Internet t
Page 25 and 26: Office of Applied Studies (2006a).
Page 27 and 28: APPENDIX A FEDERAL AND STATE OFFICI
Page 29 and 30: APPENDIX B INFORMATION SOURCES CONS
Page 31 and 32: APPENDIX C OUTSIDE EXPERTS CONSULTE
Page 33 and 34: TECHNICAL REPORT: ANALYSIS OF AVAIL
Page 35 and 36: Exhibit 3. Based on this estimate (
Page 37 and 38: Exhibit 5. DAWNLive! Continuously R
Page 39 and 40: 100% 90% 80% 70% 60% 50% 40% 30% 20
Page 41 and 42: Exhibit 12. DAWNLive! All Reporting
Page 43 and 44: increasing, especially cases involv
Page 45 and 46: See exhibits 37-44 for a full listi
Page 47 and 48: the TEDS other opiate patients were
Page 49 and 50: In the last two years, patients who
Page 51 and 52: self-medicating with buprenorphine.
Page 53 and 54: legally available in the U.S.) has
Page 55 and 56: engaging in activities such as rent
Page 57 and 58: Exhibit 33. Characteristics of Verm
Page 59: Exhibit 35. DAWN Live! ED Reports b
Page 63 and 64: 8000 7000 6000 5000 4000 3000 2000
Page 65 and 66: 400 350 300 250 200 150 100 50 0 A
Page 67 and 68: Exhibit 43. Oxycodone Items Analyze
Page 69 and 70: Exhibit 45. Total Number of Subutex
show all

Diversion and Abuse of Buprenorphine

Create successful ePaper yourself

Delete template?

Save as template?